Shuttle Pharmaceuticals (SHPH)

Radiation therapy is a widely used cancer treatment modality, but its effectiveness can be limited by tumour resistance and by the need to protect healthy tissue. Shuttle Pharmaceuticals is developing drug candidates and related technologies designed to sensitise cancer cells to radiation, enhance therapeutic response or support more personalised treatment decisions. Its work is organised as a single operating segment focused on drug development and related cancer technologies.

The company’s pipeline includes Ropidoxuridine, a candidate being developed as a radiation sensitiser; HDAC inhibitors, which are being studied for their potential role in cancer treatment; PSMA-B, a programme associated with prostate cancer targeting; and the PC-Rad Test, which is intended to help assess patient response or guide radiation-related treatment approaches. Shuttle Pharmaceuticals also references the Molecule.ai platform as part of its technology strategy, including internal development work and potential licensing opportunities.

As a clinical-stage company, Shuttle Pharmaceuticals does not operate like a diversified commercial drugmaker. Its value proposition depends on advancing its candidates through research, regulatory and clinical milestones, securing development capital and demonstrating that its technologies can improve outcomes in defined cancer settings.